Identification of bile survivin and carbohydrate antigen 199 in distinguishing cholangiocarcinoma from benign obstructive jaundice

Biomark Med. 2017 Jan;11(1):11-18. doi: 10.2217/bmm-2016-0178. Epub 2016 Nov 22.

Abstract

Aim: To investigate whether bile survivin and carbohydrate antigen 199 (CA199) can be helpful in distinguishing cholangiocarcinoma (malignant obstructive jaundice) from benign obstructive jaundice.

Methods: Receiver operating characteristic curve was used to evaluate the feasibility of bile survivin and CA199 in differentiating cholangiocarcinoma from benign obstructive jaundice.

Results: The area under the curve for survivin and CA199 in bile and serum were 0.780 (p < 0.001), 0.6 (p = 0.084), 0.746 (p < 0.001) and 0.542 (p = 0.464), respectively. Combination of bile survivin and CA199 could improve the diagnostic capability.

Conclusion: Bile survivin and CA199 are significantly increased in patients with cholangiocarcinoma and may be useful biomarkers in differentiating distinguishing cholangiocarcinoma from benign obstructive jaundice.

Keywords: bile CA199; bile survivin; cholangiocarcinoma; diagnosis; obstructive jaundice.

MeSH terms

  • Adult
  • Aged
  • Antigens, Tumor-Associated, Carbohydrate / blood*
  • Area Under Curve
  • Bile / metabolism*
  • Bile Duct Neoplasms / diagnosis*
  • Biomarkers, Tumor / analysis
  • Biomarkers, Tumor / blood
  • Cholangiocarcinoma / diagnosis*
  • Diagnosis, Differential
  • Female
  • Humans
  • Inhibitor of Apoptosis Proteins / analysis*
  • Inhibitor of Apoptosis Proteins / blood
  • Jaundice, Obstructive / diagnosis*
  • Jaundice, Obstructive / pathology
  • Male
  • Middle Aged
  • Neoplasm Staging
  • ROC Curve
  • Survivin

Substances

  • Antigens, Tumor-Associated, Carbohydrate
  • BIRC5 protein, human
  • Biomarkers, Tumor
  • Inhibitor of Apoptosis Proteins
  • Survivin
  • carbohydrate antigen 199, human